Wei Guan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wei Guan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Yan Wang
Department of Respiratory Medicine, Qinghai University Affiliated Hospital, Xining 810001, People’s Republic of China
6 shared publicationsShan Lin
Lanzhou University
4 shared publications- Shan Lin
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
4 shared publications Yingqing Shi
Department of Respiratory Medicine, Qinghai University Affiliated Hospital, Xining
4 shared publicationsDong Han
Shaanxi Provincial People's Hospital
2 shared publicationsJian-Ting Li
Qinghai university
2 shared publications
Latest Publications
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45875
Bronchoscopy-associated dissemination of pulmonary nocardiosis caused by Nocardia terpenica in an immunocompetent patient with bronchiectasis: A case report
Rationale: Bronchoscopy with bronchoalveolar lavage (BAL) is essential for diagnosing pulmonary infections; however, its potential to iatrogenically disseminate a localized Nocardia infection represents a severe and unreported risk. This case aims to alert clinicians to this danger and underscore essential therapeutic lessons for disseminated disease. Patient concerns: A 51-year-old immunocompetent woman with longstanding bronchiectasis presented with 1-day of hemoptysis and a 40-year history of chronic cough and sputum production. These symptoms had worsened over the preceding 2 months despite broad-spectrum antibiotic therapy. Diagnoses: Bronchiectasis was diagnosed based on chronic respiratory symptoms and characteristic computed tomography findings. Nocardia terpenica infection was confirmed by BAL fluid culture and metagenomic next-generation sequencing. Within 24 hours post-BAL, the patient developed fever, respiratory failure, and new bilateral consolidations on computed tomography, indicating procedure-related disseminated nocardiosis. Interventions: Diagnostic bronchoscopy with BAL was performed. Therapeutically, the patient received a total of 24 days of intensive combination therapy with intravenous imipenem/cilastatin and oral trimethoprim–sulfamethoxazole (TMP–SMX), followed by sequential long-term oral TMP–SMX monotherapy. Outcomes: The initial 10-day course of combination therapy led to rapid clinical improvement, with resolution of fever and respiratory failure within 3 days, and normalization of C-reactive protein levels by day 10. Radiographic improvement was also evident. However, relapse (recurrent fever and malaise) occurred promptly within 3 days after de-escalation to TMP–SMX monotherapy. After reinstitution of imipenem/cilastatin plus TMP–SMX for an additional 14 days (totaling 24 days of intensive therapy), the patient achieved sustained clinical and radiographic remission. She was successfully discharged on long-term TMP–SMX monotherapy and remained well at the 2-month follow-up. Lessons: This is the first report suggesting that bronchoscopy, particularly BAL, can disseminate a localized airway Nocardia infection, causing acute disseminated pulmonary nocardiosis. Extreme caution is warranted when performing bronchoscopy in bronchiectasis patients with suspected or confirmed nocardiosis. For disseminated pulmonary nocardiosis, intensive combination therapy for at least 3 weeks is mandatory to prevent relapse, regardless of a rapid initial response.
- 7 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (45) , e45875
Open AccessBronchoscopy-associated dissemination of pulmonary nocardiosis caused by Nocardia terpenica in an immunocompetent patient with bronchiectasis: A case report
Rationale: Bronchoscopy with bronchoalveolar lavage (BAL) is essential for diagnosing pulmonary infections; however, its potential to iatrogenically disseminate a localized Nocardia infection represents a severe and unreported risk. This case aims to alert clinicians to this danger and underscore essential therapeutic lessons for disseminated disease. Patient concerns: A 51-year-old immunocompetent woman with longstanding bronchiectasis presented with 1-day of hemoptysis and a 40-year history of chronic cough and sputum production. These symptoms had worsened over the preceding 2 months despite broad-spectrum antibiotic therapy. Diagnoses: Bronchiectasis was diagnosed based on chronic respiratory symptoms and characteristic computed tomography findings. Nocardia terpenica infection was confirmed by BAL fluid culture and metagenomic next-generation sequencing. Within 24 hours post-BAL, the patient developed fever, respiratory failure, and new bilateral consolidations on computed tomography, indicating procedure-related disseminated nocardiosis. Interventions: Diagnostic bronchoscopy with BAL was performed. Therapeutically, the patient received a total of 24 days of intensive combination therapy with intravenous imipenem/cilastatin and oral trimethoprim–sulfamethoxazole (TMP–SMX), followed by sequential long-term oral TMP–SMX monotherapy. Outcomes: The initial 10-day course of combination therapy led to rapid clinical improvement, with resolution of fever and respiratory failure within 3 days, and normalization of C-reactive protein levels by day 10. Radiographic improvement was also evident. However, relapse (recurrent fever and malaise) occurred promptly within 3 days after de-escalation to TMP–SMX monotherapy. After reinstitution of imipenem/cilastatin plus TMP–SMX for an additional 14 days (totaling 24 days of intensive therapy), the patient achieved sustained clinical and radiographic remission. She was successfully discharged on long-term TMP–SMX monotherapy and remained well at the 2-month follow-up. Lessons: This is the first report suggesting that bronchoscopy, particularly BAL, can disseminate a localized airway Nocardia infection, causing acute disseminated pulmonary nocardiosis. Extreme caution is warranted when performing bronchoscopy in bronchiectasis patients with suspected or confirmed nocardiosis. For disseminated pulmonary nocardiosis, intensive combination therapy for at least 3 weeks is mandatory to prevent relapse, regardless of a rapid initial response.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 787-794
Association Between the Polymorphism of Steroid Hormone Metabolism Genes and High-Altitude Pulmonary Edema in the Chinese Han Population
Purpose: Steroid hormone metabolism plays an essential role in high-altitude pulmonary edema (HAPE) progression. This study aimed to investigate the association between polymorphism in seven steroid hormone metabolism genes (STAR, HSD3B1, HSD3B2, CYP17A1, CYP21A2, CYP11B1, and CYP11B2) and HAPE susceptibility among Han Chinese. Patients and Methods: A total of 41 tagSNPs in the seven genes were genotyped using Sequenom MassARRAY SNP assays from 169 HAPE patients (HAPE-p) and 309 matched Han Chinese individuals resistant to HAPE (HAPE-r). The genotypic and allele frequencies, odds ratios (ORs), and 95% confidence intervals (95% CIs) were calculated. Results: Four SNPs, including the allele C of rs6203 (p = 0.034, OR [95% CI] = 1.344 [1.022− 1.767]) in HSD3B1, allele G of rs3740397 (p = 0.044, OR [95% CI] = 1.314 [1.007− 1.714]) and allele C of rs10786712 (p = 0.039, OR [95% CI] = 0.751 [0.572− 0.986]) in CYP17A1, and allele T of rs6402 (p = 0.006, OR [95% CI] = 0.504 [0.306− 0.830]) in CYP11B1, were significantly associated with HAPE. The distribution of the genotypes of these SNPs also significantly differed between the HAPE-p and HAPE-r groups. Moreover, six haplotypes (the linkage disequilibrium block including rs10883783, rs4919686, rs3740397, rs3824755, and rs10786712) of CYP17A1 were also significantly associated with HAPE. Conclusion: The four SNPs located in HSD3B1 (rs6203), CYP17A1 (rs3740397 and rs10786712), and CYP11B1 (rs6402) and the six haplotypes of CYP17A1 are likely to have an effect on HAPE.
- 1 January 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 787-794
Open AccessAssociation Between the Polymorphism of Steroid Hormone Metabolism Genes and High-Altitude Pulmonary Edema in the Chinese Han Population
Purpose: Steroid hormone metabolism plays an essential role in high-altitude pulmonary edema (HAPE) progression. This study aimed to investigate the association between polymorphism in seven steroid hormone metabolism genes (STAR, HSD3B1, HSD3B2, CYP17A1, CYP21A2, CYP11B1, and CYP11B2) and HAPE susceptibility among Han Chinese. Patients and Methods: A total of 41 tagSNPs in the seven genes were genotyped using Sequenom MassARRAY SNP assays from 169 HAPE patients (HAPE-p) and 309 matched Han Chinese individuals resistant to HAPE (HAPE-r). The genotypic and allele frequencies, odds ratios (ORs), and 95% confidence intervals (95% CIs) were calculated. Results: Four SNPs, including the allele C of rs6203 (p = 0.034, OR [95% CI] = 1.344 [1.022− 1.767]) in HSD3B1, allele G of rs3740397 (p = 0.044, OR [95% CI] = 1.314 [1.007− 1.714]) and allele C of rs10786712 (p = 0.039, OR [95% CI] = 0.751 [0.572− 0.986]) in CYP17A1, and allele T of rs6402 (p = 0.006, OR [95% CI] = 0.504 [0.306− 0.830]) in CYP11B1, were significantly associated with HAPE. The distribution of the genotypes of these SNPs also significantly differed between the HAPE-p and HAPE-r groups. Moreover, six haplotypes (the linkage disequilibrium block including rs10883783, rs4919686, rs3740397, rs3824755, and rs10786712) of CYP17A1 were also significantly associated with HAPE. Conclusion: The four SNPs located in HSD3B1 (rs6203), CYP17A1 (rs3740397 and rs10786712), and CYP11B1 (rs6402) and the six haplotypes of CYP17A1 are likely to have an effect on HAPE.
- Open Access
- 1 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (19) , e20055
Sleep apnea–hypopnea syndrome caused by ankylosing spondylitis
Introduction: Sleep apnea–hypopnea syndrome (SAHS) is a multifactorial disease characterized by recurrent hypopnea or respiratory interruption during sleep, which causes intermittent hypoxemia, hypercapnia, and sleep structure disturbances. An association between ankylosing spondylitis (AS) and the type of SAHS has rarely been reported in the literature. Here, we present a case of SAHS in a patient with AS and discuss the possible mechanism underlying the type of SAHS. Patient concerns: A 46-year-old man presented with a 15-year history of AS. He had been receiving sulfasalazine for symptomatic relief and had never been on immunosuppressive therapy. Diagnosis: The patient was diagnosed with SAHS in addition to AS. Interventions: We instituted treatment with methylprednisolone (5 mg, oral, daily), leflumomide (20 mg, oral, daily), bicyclol tablets (25 mg, oral, 3 times a day), and ursodeoxycholic acid tablets (10 mg/kg, oral, daily). The patient received etanercept (50 mg, sc, once a week) as his condition deteriorated. In addition, for management of SAHS symptoms, the patient received nasal continuous positive airway pressure (CPAP) during sleep. Outcomes: Six months after commencement of the treatment, the clinical manifestations of SAHS and AS had significantly improved. Conclusions: We hypothesize that patients with AS are prone to sleep apnea due to airway compression, central depression of respiration, abnormal inflammatory responses. Hence, careful assessment toward potential SAHS symptoms should be considered especially in patients with AS.
- 1 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (19) , e20055
Open AccessSleep apnea–hypopnea syndrome caused by ankylosing spondylitis
Introduction: Sleep apnea–hypopnea syndrome (SAHS) is a multifactorial disease characterized by recurrent hypopnea or respiratory interruption during sleep, which causes intermittent hypoxemia, hypercapnia, and sleep structure disturbances. An association between ankylosing spondylitis (AS) and the type of SAHS has rarely been reported in the literature. Here, we present a case of SAHS in a patient with AS and discuss the possible mechanism underlying the type of SAHS. Patient concerns: A 46-year-old man presented with a 15-year history of AS. He had been receiving sulfasalazine for symptomatic relief and had never been on immunosuppressive therapy. Diagnosis: The patient was diagnosed with SAHS in addition to AS. Interventions: We instituted treatment with methylprednisolone (5 mg, oral, daily), leflumomide (20 mg, oral, daily), bicyclol tablets (25 mg, oral, 3 times a day), and ursodeoxycholic acid tablets (10 mg/kg, oral, daily). The patient received etanercept (50 mg, sc, once a week) as his condition deteriorated. In addition, for management of SAHS symptoms, the patient received nasal continuous positive airway pressure (CPAP) during sleep. Outcomes: Six months after commencement of the treatment, the clinical manifestations of SAHS and AS had significantly improved. Conclusions: We hypothesize that patients with AS are prone to sleep apnea due to airway compression, central depression of respiration, abnormal inflammatory responses. Hence, careful assessment toward potential SAHS symptoms should be considered especially in patients with AS.
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 3755-3763
Diagnostic Accuracy of Interleukin-27 in Bronchoalveolar Lavage Fluids for Pulmonary Tuberculosis
Background: The World Health Organization states that China had 0.9 million cases of tuberculosis in 2017, accounting for 9% of cases globally. Despite a decrease in the incidence and mortality of tuberculosis in China over time, development in choosing the appropriate prevention and control of TB is required. Purpose: The aim of this study was to evaluate the diagnostic significance of interleukin-27 in bronchoalveolar lavage fluids for pulmonary tuberculosis. Materials and methods: Eventually, 107 bronchoalveolar lavage fluids from patients were included in this study. The concentrations of interleukin-27 and adenosine deaminase were determined in bronchoalveolar lavage fluids using enzyme-linked immunosorbent assay. Results: It was found that the concentrations of interleukin-27 in bronchoalveolar lavage fluids of sputum-positive pulmonary tuberculosis group were significantly higher than those in sputum-negative pulmonary tuberculosis, lung cancer, and previous pulmonary tuberculosis groups, respectively (all PConclusion: Interleukin-27 in bronchoalveolar lavage fluids is a sensitive and specific biomarker for the differential diagnosis of pulmonary tuberculosis from lung cancer and previous pulmonary tuberculosis.
- 1 December 2019
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 12, 3755-3763
Open AccessDiagnostic Accuracy of Interleukin-27 in Bronchoalveolar Lavage Fluids for Pulmonary Tuberculosis
Background: The World Health Organization states that China had 0.9 million cases of tuberculosis in 2017, accounting for 9% of cases globally. Despite a decrease in the incidence and mortality of tuberculosis in China over time, development in choosing the appropriate prevention and control of TB is required. Purpose: The aim of this study was to evaluate the diagnostic significance of interleukin-27 in bronchoalveolar lavage fluids for pulmonary tuberculosis. Materials and methods: Eventually, 107 bronchoalveolar lavage fluids from patients were included in this study. The concentrations of interleukin-27 and adenosine deaminase were determined in bronchoalveolar lavage fluids using enzyme-linked immunosorbent assay. Results: It was found that the concentrations of interleukin-27 in bronchoalveolar lavage fluids of sputum-positive pulmonary tuberculosis group were significantly higher than those in sputum-negative pulmonary tuberculosis, lung cancer, and previous pulmonary tuberculosis groups, respectively (all PConclusion: Interleukin-27 in bronchoalveolar lavage fluids is a sensitive and specific biomarker for the differential diagnosis of pulmonary tuberculosis from lung cancer and previous pulmonary tuberculosis.
- Open Access
- 15 October 2019
- Published by Springer Nature in Research Square
Quantitative CT parameters correlate with lung function in chronic obstructive pulmonary disease: a systematic review and meta-analysis
Purpose : The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods: PubMed, Embase, Cochrane and Web of Knowledge were searched by two investigators from inception to 2018, using a combination of pertinent items to discover articles that investigated the relationship between CT measurements and lung function parameters in patients with COPD. Five reviewers independently evaluated the quality, extracted data and evaluated bias. The correlation coefficient was calculated and heterogeneity was explored. The following CT measurements were extracted: percentage of lung attenuation area < -950 Hounsfield Units (HU), mean lung density, percentage of airway wall area, air trapping index, airway wall thickness. Two airflow obstruction parameters were extracted: forced expiratory volume in the first second as a percentage of prediction (FEV 1 % pred) and FEV 1 divided by forced expiratory volume lung capacity. Results: A total of 117 studies (19,942 participants) were identified, 36 of which (4,762 participants) were suitable for meta-analysis. Results from our analysis demonstrated that there was a significant correlation between quantitative CT parameters and lung function. The absolute pooled correlation coefficients ranged from 0.44 (95% CI, 0.36 to 0.53) to 0.71(95% CI,0.65 to 0.77) for inspiratory CT and 0.59 (95% CI, 0.53 to 0.65) to 0.66 (95% CI,0.61 to 0.72) for expiratory CT. Conclusions: Results from this analysis demonstrated that quantitative CT parameters are significantly correlated with lung function in patients with COPD. With recent advances in chest CT, we can evaluate morphological features in the lungs that cannot be obtained by other clinical indices, such as pulmonary function tests. Therefore, CT can provide a quantitative method to advance the development and testing of new interventions and therapies for patients with COPD. Keywords: Airway obstruction, Systematic review, Meta-analysis.
- 15 October 2019
- Published by Springer Nature in Research Square
Open AccessQuantitative CT parameters correlate with lung function in chronic obstructive pulmonary disease: a systematic review and meta-analysis
Purpose : The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods: PubMed, Embase, Cochrane and Web of Knowledge were searched by two investigators from inception to 2018, using a combination of pertinent items to discover articles that investigated the relationship between CT measurements and lung function parameters in patients with COPD. Five reviewers independently evaluated the quality, extracted data and evaluated bias. The correlation coefficient was calculated and heterogeneity was explored. The following CT measurements were extracted: percentage of lung attenuation area < -950 Hounsfield Units (HU), mean lung density, percentage of airway wall area, air trapping index, airway wall thickness. Two airflow obstruction parameters were extracted: forced expiratory volume in the first second as a percentage of prediction (FEV 1 % pred) and FEV 1 divided by forced expiratory volume lung capacity. Results: A total of 117 studies (19,942 participants) were identified, 36 of which (4,762 participants) were suitable for meta-analysis. Results from our analysis demonstrated that there was a significant correlation between quantitative CT parameters and lung function. The absolute pooled correlation coefficients ranged from 0.44 (95% CI, 0.36 to 0.53) to 0.71(95% CI,0.65 to 0.77) for inspiratory CT and 0.59 (95% CI, 0.53 to 0.65) to 0.66 (95% CI,0.61 to 0.72) for expiratory CT. Conclusions: Results from this analysis demonstrated that quantitative CT parameters are significantly correlated with lung function in patients with COPD. With recent advances in chest CT, we can evaluate morphological features in the lungs that cannot be obtained by other clinical indices, such as pulmonary function tests. Therefore, CT can provide a quantitative method to advance the development and testing of new interventions and therapies for patients with COPD. Keywords: Airway obstruction, Systematic review, Meta-analysis.
- Open Access
- 19 June 2019
- Published by Springer Nature in Research Square
Quantitative CT parameters correlate with lung function in chronic obstructive pulmonary disease: a systematic review and meta-analysis
Background The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods PubMed, Embase, Cochrane and Web of Knowledge were searched by two investigators from inception to 2018, using a combination of pertinent items to discover articles that investigated the relationship between CT measurements and lung function parameters in patients with COPD. Five reviewers independently evaluated the quality, extracted data and evaluated bias. The correlation coefficient was calculated and heterogeneity was explored. The following CT measurements were extracted: percentage of lung attenuation area < -950 Hounsfield Units (HU), mean lung density, percentage of airway wall area, air trapping index, airway wall thickness. Two airflow obstruction parameters were extracted: forced expiratory volume in the first second as a percentage of prediction (FEV1% pred) and FEV1 divided by forced expiratory volume lung capacity. Results A total of 117 studies (19,942 participants) were identified, 36 of which (4,762 participants) were suitable for meta-analysis. Results from our analysis demonstrated that there was a significant correlation between quantitative CT parameters and lung function. The absolute pooled correlation coefficients ranged from 0.44 (95% CI, 0.36 to 0.53) to 0.71(95% CI,0.65 to 0.77) for inspiratory CT and 0.59 (95% CI, 0.53 to 0.65) to 0.66 (95% CI,0.61 to 0.72) for expiratory CT. Conclusions Results from this analysis demonstrated that quantitative CT parameters are significantly correlated with lung function in patients with COPD. With recent advances in chest CT, we can evaluate morphological features in the lungs that cannot be obtained by other clinical indices, such as pulmonary function tests. Therefore, CT can provide a quantitative method to advance the development and testing of new interventions and therapies for patients with COPD .
- 19 June 2019
- Published by Springer Nature in Research Square
Open AccessQuantitative CT parameters correlate with lung function in chronic obstructive pulmonary disease: a systematic review and meta-analysis
Background The aim of the study was to analyze the correlation between quantitative computed tomography (CT) parameters and airflow obstruction in patients with chronic obstruction pulmonary disease (COPD). Methods PubMed, Embase, Cochrane and Web of Knowledge were searched by two investigators from inception to 2018, using a combination of pertinent items to discover articles that investigated the relationship between CT measurements and lung function parameters in patients with COPD. Five reviewers independently evaluated the quality, extracted data and evaluated bias. The correlation coefficient was calculated and heterogeneity was explored. The following CT measurements were extracted: percentage of lung attenuation area < -950 Hounsfield Units (HU), mean lung density, percentage of airway wall area, air trapping index, airway wall thickness. Two airflow obstruction parameters were extracted: forced expiratory volume in the first second as a percentage of prediction (FEV1% pred) and FEV1 divided by forced expiratory volume lung capacity. Results A total of 117 studies (19,942 participants) were identified, 36 of which (4,762 participants) were suitable for meta-analysis. Results from our analysis demonstrated that there was a significant correlation between quantitative CT parameters and lung function. The absolute pooled correlation coefficients ranged from 0.44 (95% CI, 0.36 to 0.53) to 0.71(95% CI,0.65 to 0.77) for inspiratory CT and 0.59 (95% CI, 0.53 to 0.65) to 0.66 (95% CI,0.61 to 0.72) for expiratory CT. Conclusions Results from this analysis demonstrated that quantitative CT parameters are significantly correlated with lung function in patients with COPD. With recent advances in chest CT, we can evaluate morphological features in the lungs that cannot be obtained by other clinical indices, such as pulmonary function tests. Therefore, CT can provide a quantitative method to advance the development and testing of new interventions and therapies for patients with COPD .
- Open Access
- 1 May 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 1527-1533
Dabigatran must be used carefully: literature review and recommendations for management of adverse events
Atrial fibrillation increases the risk of stroke and death. The vitamin-K antagonist warfarin is recommended for patients with atrial fibrillation, but vitamin-K antagonists are cumbersome to use. Therefore, an effective, safe and convenient new anticoagulant is needed. Dabigatran acts by inhibiting free and fibrin-bound thrombin directly. It is an oral anticoagulant that was approved by the US Food and Drug Administration. The oral anticoagulant dabigatran has been used increasingly due to its good tolerance, predictable pharmacokinetics, effective anticoagulant effects, and absence of requirement of coagulation monitoring. However, an increasing prevalence of adverse events has been reported, some of them quite serious. Therefore, we searched and reviewed the literature on dabigatran with regard to adverse events, and proposed solutions to prevent and reduce the chance of adverse events occurring.
- 1 May 2019
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 13, 1527-1533
Open AccessDabigatran must be used carefully: literature review and recommendations for management of adverse events
Atrial fibrillation increases the risk of stroke and death. The vitamin-K antagonist warfarin is recommended for patients with atrial fibrillation, but vitamin-K antagonists are cumbersome to use. Therefore, an effective, safe and convenient new anticoagulant is needed. Dabigatran acts by inhibiting free and fibrin-bound thrombin directly. It is an oral anticoagulant that was approved by the US Food and Drug Administration. The oral anticoagulant dabigatran has been used increasingly due to its good tolerance, predictable pharmacokinetics, effective anticoagulant effects, and absence of requirement of coagulation monitoring. However, an increasing prevalence of adverse events has been reported, some of them quite serious. Therefore, we searched and reviewed the literature on dabigatran with regard to adverse events, and proposed solutions to prevent and reduce the chance of adverse events occurring.
- Open Access
- 18 April 2019
- Published by Springer Nature in Journal of Physiological Anthropology
- Vol. 38 (1) , 4
NR3C1 gene polymorphisms are associated with high-altitude pulmonary edema in Han Chinese
Background: High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic edema which occurs in unacclimatized individuals after rapid ascent to high altitude. NR3C1 gene encodes for glucocorticoid receptor (GR) which plays an important role in stress and inflammation. This study aimed to investigate the association of NR3C1 polymorphisms with the susceptibility to HAPE in Han Chinese. Methods: The 30 SNPs in the NR3C1 gene were genotyped by the Sequenom MassARRAY SNP assay in 133 HAPE patients (HAPE-p) and 135 matched Han Chinese resistant to HAPE (HAPE-r). The genotypic and allele frequencies, odds ratios (ORs), and 95% confidence intervals (95% CIs) were calculated, respectively. Results: The 12 SNPs showed a significant difference between the HAPE-p and HAPE-r groups. In allelic model analysis, we found that the allele “A” of rs17287745, rs17209237, rs17209251, rs6877893, and rs1866388; the allele “C” of rs6191, rs6188, and rs2918417; the allele “T” of rs33388 and rs4634384; and the allele “G” of rs41423247 and rs10052957 were associated with increased the risk of HAPE. In the genetic model analysis, we found that rs17287745, rs6191, rs6188, rs33388, rs2918417, rs6877893, rs1866388, rs41423247, rs4634384, and rs10052957 were relevant to the increased HAPE risk under the dominant model. In addition, the haplotype AACACTCAAGTG of the 12 SNPs was detected to be significantly associated with HAPE risk (OR = 2.044, 95%CI = 1.339~3.120, P = 0.0008), while the haplotype GGAGCACGACCG was associated with the decreased risk of HAPE (OR = 0.573, 95% CI = 0.333~0.985, P = 0.0422). Conclusions: Our findings provide new evidence for the association between SNPs in NR3C1 and an increased risk of HAPE in the Chinese population. NR3C1 polymorphisms are associated with the susceptibility to HAPE in Han Chinese.
- 18 April 2019
- Published by Springer Nature in Journal of Physiological Anthropology
- Vol. 38 (1) , 4
Open AccessNR3C1 gene polymorphisms are associated with high-altitude pulmonary edema in Han Chinese
Background: High-altitude pulmonary edema (HAPE) is a life-threatening form of non-cardiogenic edema which occurs in unacclimatized individuals after rapid ascent to high altitude. NR3C1 gene encodes for glucocorticoid receptor (GR) which plays an important role in stress and inflammation. This study aimed to investigate the association of NR3C1 polymorphisms with the susceptibility to HAPE in Han Chinese. Methods: The 30 SNPs in the NR3C1 gene were genotyped by the Sequenom MassARRAY SNP assay in 133 HAPE patients (HAPE-p) and 135 matched Han Chinese resistant to HAPE (HAPE-r). The genotypic and allele frequencies, odds ratios (ORs), and 95% confidence intervals (95% CIs) were calculated, respectively. Results: The 12 SNPs showed a significant difference between the HAPE-p and HAPE-r groups. In allelic model analysis, we found that the allele “A” of rs17287745, rs17209237, rs17209251, rs6877893, and rs1866388; the allele “C” of rs6191, rs6188, and rs2918417; the allele “T” of rs33388 and rs4634384; and the allele “G” of rs41423247 and rs10052957 were associated with increased the risk of HAPE. In the genetic model analysis, we found that rs17287745, rs6191, rs6188, rs33388, rs2918417, rs6877893, rs1866388, rs41423247, rs4634384, and rs10052957 were relevant to the increased HAPE risk under the dominant model. In addition, the haplotype AACACTCAAGTG of the 12 SNPs was detected to be significantly associated with HAPE risk (OR = 2.044, 95%CI = 1.339~3.120, P = 0.0008), while the haplotype GGAGCACGACCG was associated with the decreased risk of HAPE (OR = 0.573, 95% CI = 0.333~0.985, P = 0.0422). Conclusions: Our findings provide new evidence for the association between SNPs in NR3C1 and an increased risk of HAPE in the Chinese population. NR3C1 polymorphisms are associated with the susceptibility to HAPE in Han Chinese.
- Open Access
- 31 January 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (3) , 580-582
Fatal middle cerebral artery aneurysm from Mycobacterium tuberculosis infection
Key Clinical Message: Aneurysms caused by Mycobacterium tuberculosis infection are a rare disease. For such patients, cerebral artery aneurysm is a rare but evenly fatal lesion that is not diagnosed in time; combined antituberculosis treatment and surgical intervention provide the best chance of cure.
- 31 January 2019
- Published by Wiley in Clinical Case Reports
- Vol. 7 (3) , 580-582
Open AccessFatal middle cerebral artery aneurysm from Mycobacterium tuberculosis infection
Key Clinical Message: Aneurysms caused by Mycobacterium tuberculosis infection are a rare disease. For such patients, cerebral artery aneurysm is a rare but evenly fatal lesion that is not diagnosed in time; combined antituberculosis treatment and surgical intervention provide the best chance of cure.
- Open Access
- 1 December 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (49) , e13578
Pulmonary embolism caused by myasthenia gravis
Pulmonary embolism (PE) is a relatively common disease; however, myasthenia gravis leading to PE has been rarely reported in the literature. We report a case of PE in a patient with myasthenia gravis and discuss the possible mechanism underlying the development of PE. We hypothesize that inflammatory mediators may lead to endothelial injury, resulting in PE or deep venous thrombosis (DVT) in patients with myasthenia gravis. A 45-year-old woman had a 9-year history of myasthenia gravis. She was receiving neostigmine bromide for symptomatic relief and had never been on immunosuppressive therapy. Myasthenia gravis and pulmonary embolism. Our patient was treated with low-molecular-weight heparin immediately after hospital admission. Thrombolytic therapy was later initiated as her condition deteriorated. After 2 weeks, the pulmonary artery systolic pressure on echocardiography reduced to 60 mm Hg, and venous ultrasonography showed no evidence of DVT. Her computed tomography pulmonary angiogram revealed a mural thrombus in both the main pulmonary arteries. She refused to undergo immunosuppressive therapy; hence, she was discharged on neostigmine bromide and warfarin. There was no recurrence of PE or DVT at 3- and 6-month follow-ups. Patients with an autoimmune-mediated disease may have an increased risk of DVT and PE. We hypothesize that the risk may increase in the absence of immunosuppressive therapy. Hence, anticoagulant therapy may be administered early to reduce mortality from acute PE.
- 1 December 2018
- Published by Wolters Kluwer Health in Medicine
- Vol. 97 (49) , e13578
Open AccessPulmonary embolism caused by myasthenia gravis
Pulmonary embolism (PE) is a relatively common disease; however, myasthenia gravis leading to PE has been rarely reported in the literature. We report a case of PE in a patient with myasthenia gravis and discuss the possible mechanism underlying the development of PE. We hypothesize that inflammatory mediators may lead to endothelial injury, resulting in PE or deep venous thrombosis (DVT) in patients with myasthenia gravis. A 45-year-old woman had a 9-year history of myasthenia gravis. She was receiving neostigmine bromide for symptomatic relief and had never been on immunosuppressive therapy. Myasthenia gravis and pulmonary embolism. Our patient was treated with low-molecular-weight heparin immediately after hospital admission. Thrombolytic therapy was later initiated as her condition deteriorated. After 2 weeks, the pulmonary artery systolic pressure on echocardiography reduced to 60 mm Hg, and venous ultrasonography showed no evidence of DVT. Her computed tomography pulmonary angiogram revealed a mural thrombus in both the main pulmonary arteries. She refused to undergo immunosuppressive therapy; hence, she was discharged on neostigmine bromide and warfarin. There was no recurrence of PE or DVT at 3- and 6-month follow-ups. Patients with an autoimmune-mediated disease may have an increased risk of DVT and PE. We hypothesize that the risk may increase in the absence of immunosuppressive therapy. Hence, anticoagulant therapy may be administered early to reduce mortality from acute PE.